PARTNERING

 

Our business model, expertise, and diverse team have made us a partner of choice for biotechnology and pharmaceutical companies working on serious liver diseases.

 
 
Partnering-banner.jpg
 

CURRENT PARTNERSHIPS

Click below to learn more

 


 
 
 

Partner with Us

 

We are currently interested in collaboration opportunities related to our liver disease portfolio and programs for outlicensing.

To initiate a partnering discussion, visit us at an upcoming event or email us at partnering@bostonpharmaceuticals.com

 
 
AdobeStock_340532559.jpeg
 
 

OUTLICENSING OPPORTUNITIES

Boston Pharmaceuticals is committed to working with the best partners to bring medicines to patients. We currently have multiple collaboration opportunities, including the programs available for out-licensing listed below:

Compound: BOS161721  (avizakimab)
IL-21 Mab for Lupus

Pre-Clin
P1
P2
P3

Compound: BOS-475
BETi for Psoriasis (topical)

Pre-Clin
P1
P2
P3

Compound: BOS-857
Furin Inhibitors for Fibrosis Resolution

Pre-Clin
P1
P2
P3